Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Toshko Lissitchkov MD, PhD"'
Autor:
Jerzy Windyga MD, PhD, Margarita Timofeeva MD, Oleksandra Stasyshyn MD, PhD, Vasily Mamonov MD, PhD, José Luis Lamas Castellanos MD, Toshko Lissitchkov MD, PhD, Krzysztof Chojnowski MD, PhD, Miranda Chapman BSc, Borislava G. Pavlova PhD, Srilatha Tangada PhD
Publikováno v:
Clinical and Applied Thrombosis/Hemostasis, Vol 26 (2020)
Hemostatic management is essential for ensuring the safety of patients with hemophilia during surgery. This phase 3, prospective, uncontrolled trial, evaluated hemostatic efficacy, consumption, and safety of a recombinant factor IX concentrate, nonac
Externí odkaz:
https://doaj.org/article/7998488d886248d198a60d98265dfc0e
Autor:
Jerzy Windyga MD, PhD, Oleksandra Stasyshyn MD, PhD, Toshko Lissitchkov MD, PhD, Vasily Mamonov MD, PhD, Margit Serban MD, PhD, Luminita Rusen MD, PhD, Bettina Ploder MSc, Srilatha Tangada PhD
Publikováno v:
Clinical and Applied Thrombosis/Hemostasis, Vol 26 (2020)
This phase 3, prospective, open-label, multicenter, continuation study (NCT01286779) investigated the use of a recombinant factor IX (FIX), nonacog gamma (BAX 326, RIXUBIS ® ) in patients with severe or moderately severe hemophilia B. The study popu
Externí odkaz:
https://doaj.org/article/53acbf307856414a98abc07531c9dfd7